Massive Real-World study investigates rare eye inflammation after common injection
NCT ID NCT07105228
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study analyzed data from nearly 290,000 patients who received aflibercept (Eylea) injections for various retinal diseases. The goal was to estimate how often retinal vasculitis (inflammation of blood vessels in the eye) occurs in real-world clinical practice. Researchers looked at medical records from 2017 to 2024 to identify cases and describe patient characteristics.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- aflibercept (Eylea)
- What this could lead to
- If successful, this study could help doctors better understand the risk of retinal vasculitis in patients receiving aflibercept injections.
- What could go wrong
- This is an observational study using existing data, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
290,000 people
The number who actually took part.
- Started
-
Jul 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will represent patients and patient-eyes who initiate aflibercept 2 mg injections
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for Patient Population: 1\. All aflibercept injections identified by the Healthcare Common Procedure Coding System (HCPCS) or National Drug Code (NDC) from January 1, 2017, to February 29, 2024, as recorded in the Komodo close claims database. Key Exclusion Criteria: 1. Aflibercept injections with unspecified laterality will be excluded 2. Aflibercept injections from individuals aged \<18 years or those with unknown age on the injection date will be excluded 3. Patient-eyes with a diagnosis of RV in the same eye as the aflibercept injection or with unspecified laterality within 12 months (365 days) prior to index date (inclusive), as defined in the protocol 4. Patient-eyes that do not meet the continuous enrollment requirement will be excluded 5. Aflibercept injections will be excluded if there is ≥1 other anti-VEGF injection administered on the same date NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Retinal vasculitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regeneron Research Site
Tarrytown, New York, 10591, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.